Abstract
Background
Patients with nonalcoholic fatty liver disease (NAFLD) are highly at risk for cardiovascular disease (CVD). However, the risk of developing CVD in patients with lean NAFLD is not yet fully understood. Therefore, this study aimed to compare the CVD incidence in Japanese patients with lean NAFLD and those with non-lean NAFLD.
Methods
A total of 581 patients with NAFLD (219 with lean and 362 with non-lean NAFLD) were recruited. All patients underwent annual health checkups for at least 3 years, and CVD incidence was investigated during follow-up. The primary end-point was CVD incidence at 3 years.
Results
The 3-year new CVD incidence rates in patients with lean and non-lean NAFLD were 2.3% and 3.9%, respectively, and there was no significant difference between two groups (p = 0.3). Multivariable analysis adjusted for age, sex, hypertension, diabetes, and lean NAFLD/non-lean NAFLD revealed that age (every 10 years) as an independent factor associated with CVD incidence with an odds ratio (OR) of 2.0 (95% confidence interval [CI]: 1.3–3.4), whereas lean NAFLD was not associated with CVD incidence (OR: 0.6; 95% CI: 0.2–1.9).
Conclusions
CVD incidence was comparable between patients with lean NAFLD and those with non-lean NAFLD. Therefore, CVD prevention is needed even in patients with lean NAFLD.
Keywords: NAFLD, Lean NAFLD, Non-lean NAFLD, Cardiovascular disease
Background
Nonalcoholic fatty liver disease (NAFLD) currently occurs in > 25% of the world population and is one of the major health problems [1–5]. Patients with NAFLD have high risk for developing liver-related events including hepatocellular carcinoma and decompensation. Prevention and early detection of these complications are important clinical issue [6–10]. Because NAFLD is a disease associated with metabolic syndrome and is frequently complicated by diabetes and hyperlipidemia [11–13], patients with NAFLD are also highly at risk for cardiovascular disease (CVD) events [14, 15]. CVD has been known to more frequently occur in patients with NAFLD than in the general population [16]. Therefore, CVD prevention is an important issue that should be considered in patients with NAFLD [17–20]. Because NAFLD is strongly associated with metabolic syndrome, many patients with NAFLD are obese. However, some patients have lean NAFLD (defined as a BMI of < 25 kg/m2 in Western subjects and < 23 kg/m2 in Asian subjects) [21]. In addition, whether lean NAFLD is associated with disease progression, especially the risk of developing CVD, is not yet fully understood. Furthermore, the rate of lean NAFLD varies by race and region [22]. Therefore, even among patients with lean NAFLD, the risk of CVD may also differ by race and region, and the association between each of these factors and CVD risk remains to be verified. Therefore, this study aimed to examine whether CVD incidence differs between lean and non-lean NAFLD in Japanese patients.
Methods
Study protocol
This is a single-center, retrospective study of 5171 patients who underwent health checkup at Musashino Red Cross Hospital from January 2017 to May 2022. A total of 1351 patients with NAFLD were included, excluding 1178 with a history of alcohol consumption (defined as daily alcohol consumption of at least 30 g/day of ethanol for men and 20 g/day for women [23]), 2597 without fatty liver, and 45 with missing data. Patients underwent annual health checkups at least 3 years. After excluding 711 patients who did not reach a 3-year follow-up and 59 with a history of CVD, 581 patients were finally analyzed: 219 patients with lean NAFLD (BMI < 23 kg/m2) and 362 patients with non-lean NAFLD (BMI ≥ 23 kg/m2) (Fig. 1). This study was conducted following the principles of the Declaration of Helsinki and with the consent of the ethics committee of the institution where the study was conducted (Approval Number: 1005). We obtained consent from all patients using an opt-out approach.
Fig. 1.
Study flow chart
Clinical and laboratory data
Age, sex, weight, smoking history, alcohol intake, and blood test data were recorded on the date of the first medical checkup.
Definition of fatty liver
Ultrasonographic findings of parenchymal brightness, liver-to-kidney contrast, deep beam attenuation, and bright vessel walls were considered indicators of a fatty liver at the first medical checkup [24, 25].
Definition of comorbidity status
Diabetes mellitus was defined as a fasting plasma glucose level of ≥ 126 mg/dL, hemoglobin A1c (HbA1c) level of ≥ 6.5%, or use of any antihyperglycemic medication [26]. Dyslipidemia was defined as elevated triglycerides (≥ 150 mg/dL), elevated low-density lipoprotein (≥ 140 mg/dL), decreased high-density lipoprotein (< 40 mg/dL in men and < 50 mg/dL in women), or use of any lipid-lowering medication [27]. Hypertension was defined as systolic blood pressure of ≥ 140 mmHg, diastolic blood pressure of ≥ 90 mmHg, or use of any antihypertensive medication [28]. Significant alcohol consumption was defined as > 30 and > 20 g/week in men and women, respectively [23].
Diagnosis of CVD
CVD was defined as ischemic heart disease, heart failure, cerebrovascular disease, and peripheral arterial disease. Its incidence was investigated through interviews at the time of annual health checkups or from medical records.
Primary outcome
The primary outcome was the occurrence of new cardiovascular events within 3 years, and the incidence of cardiovascular events in patients with lean and non-lean NAFLD was compared.
Statistical analysis
Patient backgrounds of lean and non-lean NAFLD were compared using Student’s t-test or Fisher’s exact test. Logistic analysis was used to compare factors associated with new CVD events over 3 years. The logistic analysis included the following factors: age, gender, diabetes, hypertension, dyslipidemia as well as lean or non-lean NAFLD. Of these metabolic associated factors (diabetes, hypertension, and dyslipidemia), factors that were significant in univariate analysis were entered into the multivariate analysis. P-values of < 0.05 were considered statistically significant. All statistical analyses were performed using EZR [29].
Results
Patient characteristics
The numbers of patients with lean and non-lean NAFLD were 219 and 362, respectively. The mean ± standard deviation values of the patients’ age were 58 ± 12 and 59 ± 11 years, respectively, without significant differences between the two groups (p = 0.8). A total of 110 (50.2%) and 220 (60.8%) males had lean and non-lean NAFLD, respectively (p = 0.02); 47 (21.5%) and 138 (38.1%) had hypertension (p < 0.01); and 20 (9.1%) and 57 (15.7%) had diabetes (p = 0.02). In the non-lean NAFLD group, rates of men, hypertension, and diabetes were significantly higher than the lean-NAFLD group. Dyslipidemia was observed in 108 (49.3%) and 201 (55.5%) (p = 0.2) and smoking history was observed in 23 (10.5%) and 44 (12.2%) patients (p = 0.6; Table 1) in the lean and non-lean NAFLD groups, respectively. The median (interquartile range) systolic and diastolic blood pressure of patients with hypertension was 128 (118–142) and was 81 (74–87] mmHg, respectively. HbA1c of patients with diabetes was 6.8 (6.5–7.2] % and low-density lipoprotein cholesterol of patients with dyslipidemia was 143 (110–158) mg/dL.
Table 1.
Characteristics of patients with NAFLD
| Lean n = 219 |
Non-Lean n = 362 |
P Value | |
|---|---|---|---|
| Age, years | 58 ± 12 | 59 ± 11 | p = 0.8 |
| Gender, male (%) | 110 (50.2%) | 220 (60.8%) | p = 0.02 |
| BMI, kg/m2 | 21.5 ± 1.1 | 26.2 ± 2.8 | p < 0.01 |
| Smoking | 23(10.5%) | 44 (12.2%) | p = 0.6 |
| Dyslipidemia | 108 (49.3%) | 201 (55.5%) | p = 0.2 |
| Hypertension | 47 (21.5%) | 138 (38.1%) | p < 0.01 |
| Diabetes | 20 (9.1%) | 57 (15.7%) | p = 0.02 |
| AST, IU/L | 22 ± 6 | 24 ± 8 | p < 0.01 |
| ALT, IU/L | 23 ± 11 | 27 ± 13 | p < 0.01 |
| Albumin, g/dL | 4.3 ± 0.3 | 4.3 ± 0.2 | p = 0.4 |
| GGT, IU/L | 30 ± 22 | 39 ± 34 | p < 0.01 |
| Platelet counts, 109/L | 237 ± 55 | 236 ± 61 | p = 0.8 |
| Total cholesterol, mg/dL | 205 ± 33 | 204 ± 33 | p = 0.8 |
| Triglycerides, mg/dL | 104 ± 64 | 127 ± 71 | p < 0.01 |
| HDL, mg/dL | 64 ± 15 | 58 ± 14 | p < 0.01 |
| LDL, mg/dL | 124 ± 27 | 126 ± 29 | p = 0.5 |
Continuous data are shown in the mean ± standard deviation (SD). P value indicates difference between Lean and Non-Lean
Abbreviations: BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT gamma-glutamyl transpeptidase, HDL high-density lipoprotein, LDL low-density lipoprotein
The percentage of new CVD incidence in 3 years
The 3-year incidence rates of new CVD in the lean and non-lean NAFLD groups were 2.3% and 3.9%, respectively, without a significant difference (p = 0.3, Fig. 2). In the lean NAFLD group, 5 of 219 patients developed CVD: 4 cerebral infarctions and 1 myocardial infarction. In the non-lean NAFLD group, 14 of 362 patients developed CVD: 4 cerebral infarctions, 2 transit ischemic attacks, 2 heart failure, 4 myocardial infarctions, and 2 peripheral artery diseases.
Fig. 2.
The percentage of new incident CVD in 3 years
Factors of new CVD incidence in 3 years
Factors associated with the development of new CVD were examined. Multivariate analysis revealed that age (in every 10 years) (odds ratio [OR]: 2.0; 95% confidence interval [CI]: 1.3–3.4; p < 0.01) was an independent factor associated with the development of new CVD, whereas lean NAFLD (OR: 0.6; 95% CI: 0.2–1.9; p = 0.4) was not associated with CVD development (Table 2).
Table 2.
Factors of new cardiovascular disease incidence with NAFLD in 3 years
| Univariable OR (95% CI) | P Value | Multivariable OR (95% CI) | P Value | |
|---|---|---|---|---|
| Age (every 10 years) | 2.2 (1.4–3.4) | p < 0.01 | 2.0 (1.3–3.4) | p < 0.01 |
| Gender, male (%) | 1.3 (0.5–3.4) | p = 0.6 | 1.0 (0.4–2.9) | p = 0.9 |
| Lean | 0.6 (0.2–1.6) | p = 0.3 | 0.6 (0.2–1.9) | p = 0.4 |
| Hypertension | 3.9 (1.5–9.9) | p<0.01 | 2.6 (0.9–7.4) | p = 0.07 |
| Dyslipidemia | 0.3 (0.1–1.2) | p = 0.2 | ||
| Diabetes | 3.2 (1.2–8.7) | p = 0.02 | 1.6 (0.5–4.8) | p = 0.4 |
Discussion
Primary findings
This study found that lean NAFLD had a similar CVD risk as non-lean NAFLD. Patients with lean NAFLD had a lower prevalence of diabetes and hypertension compared to patients with non-lean NAFLD. However, after adjusting for these factors, no difference was observed in the CVD risk between lean and non-lean NAFLD. Therefore, lean NAFLD should be treated with the same caution for CVD development as non-lean NAFLD.
In context with published literature
The significance of disease progression in lean NAFLD is not yet fully clarified. In particular, reports comparing the CVD incidence between lean and non-lean NAFLD are limited. A study that primarily included Hispanics (40.8% of whom had NAFLD without obesity) in the United States reported no significant difference in the incidence of new CVD between the lean and non-lean NAFLD groups [30]. Conversely, a study that included mainly Caucasians (approximately 10% of participants had lean NAFLD) in the United States revealed that lean NAFLD has a lower incidence of CVD compared to non-lean NAFLD [31]. Another study that included mainly Asian in China showed that the CVD risk was lower in lean NAFLD than in non-lean NAFLD [32]. Thus, whether CVD risk was higher in lean NAFLD than in non-lean NAFLD remains unclear. Furthermore, genetic polymorphisms such as PNPLA3 are associated with the development of lean NAFLD [33–35]. Because these genetic polymorphisms vary by race, the prevalence of lean NAFLD also varies by race. The prevalence of lean NAFLD varies from 7% in the United States [36] to 19% in Asia [37, 38]. Therefore, racial differences may affect the CVD risk in lean NAFLD and regional validation is needed. In this study, the proportion of lean NAFLD was 37.6%, which is higher than that in other studies. In this situation, this study revealed that lean NAFLD has the same CVD risk as non-lean NAFLD. The results provide further insight into the risk of CVD in patients with lean NAFLD.
The prevalence of dyslipidemia, hypertension and diabetes are higher in patients with non-lean NAFLD. In several previous studies demonstrated that patients with lean NAFLD had a similar incidence of CVD compared to non-lean NAFLD [30, 39]. Focusing on patient characteristics, diabetes, dyslipidemia, and hypertension were well controlled even in patients with non-lean NAFLD and it may affect the less impact on the CVD incidence.
Strengths and limitations
The strength of this study is that all patients received annual health checkup with the uniform protocol, which enabled an accurate assessment of new CVD development. In this study, the proportion of lean NAFLD was 37.6%, which is higher than that in other studies. In a previous study that investigated the epidemiology of NAFLD in Japan with a focus on lean NAFLD, the proportion of patients with lean NAFLD in Japan was 20.7%, which was lower than in our study [40]. Patient characteristics were similar between the previous study and this study. One reason for the difference in the prevalence of lean NAFLD is that this study was conducted in subjects with health check-up with at least more than 3 years of follow-up and the cohort is not a hospital or population-based cohort. Therefore, further validation studies with a hospital or population-based cohort are needed. This study was conducted at a single institution (in Japan only), there were a limited number of cases, and the results were only available for 3 years. Thus, the results may differ with more cases or longer-term observation.
Future implications
NAFLD is a risk factor for hepatocellular carcinoma and decompensation as well as CVD [41–43]. However, the risk of CVD in lean NAFLD has not been fully elucidated. Our study shows that the CVD risk in lean NAFLD is as high as in non-lean NAFLD, indicating that even lean NAFLD should be considered a risk factor for CVD. The study was conducted in a population with a high proportion of lean NAFLD and the results provide a new insight associated with CVD risk in patients with lean NAFLD. These results provide important guidelines for the treatment of NAFLD. Recently, the new concept of metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed to detect high risk patients for complications. A previous study demonstrated that MAFLD better identified patients with worsening of CVD risk than NAFLD [14]. Investigation for the association between MAFLD and CVD incidence is also needed in a future study.
Conclusions
In conclusion, CVD incidence was comparable between patients with lean NAFLD and those with non-lean NAFLD. Therefore, CVD prevention is needed even in patients with lean NAFLD.
Acknowledgements
Not applicable.
Abbreviations
- NAFLD
Nonalcoholic fatty liver disease
- CVD
Cardiovascular disease
- BMI
Body mass index
- ALT
Alanine aminotransferase
- AST
Aspartate aminotransferase
- GGT
Gamma-glutamyl transpeptidase
- HDL
High-density lipoprotein
- MAFLD
Metabolic dysfunction-associated fatty liver disease
- LDL
Low-density lipoprotein
Authors’ contributions
Study concept and design; S.I and N.T. data acquisition; All authors. data analysis and interpretation; S.I and N.T. drafting of the manuscript; S.I and N.T. critical revision of the manuscript for important intellectual content; M.K, N.I. obtained funding; N.T, M.K. study supervision; M.K, N.I. All authors have read the final manuscript and approved it.
Funding
Masayuki Kurosaki receives funding support from Japan Agency for Medical Research and Development (grant number: JP23fk0210123h0001). Nobuharu Tamaki receives funding support from Japan Agency for Medical Research and Development (grant number: JP22fk0210111h0001, JP22fk0210104h0001).
Availability of data and materials
The datasets generated and analyzed during the current study are not publicly available due (because the datasets have personal information) but are available from the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
This study was conducted following the principles of the Declaration of Helsinki and with the consent of the ethics committee of the institution where the study was conducted (Musashino Red Cross Hospital, Approval Number: 1005). Informed consent was obtained from all study participants.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Shun Ishido and Nobuharu Tamaki contributed equally to the study.
Contributor Information
Masayuki Kurosaki, Email: kurosakim@gmail.com.
Namiki Izumi, Email: nizumi614@gmail.com.
References
- 1.Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi: 10.1038/nrgastro.2017.109. [DOI] [PubMed] [Google Scholar]
- 2.Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–690. doi: 10.1038/nrgastro.2013.171. [DOI] [PubMed] [Google Scholar]
- 3.Sumida Y, Shima T, Mitsumoto Y, Katayama T, Umemura A, Yamaguchi K, et al. Epidemiology: pathogenesis, and diagnostic strategy of diabetic liver disease in Japan. Int J Mol Sci. 2020;21(12):4337. doi: 10.3390/ijms21124337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Tampi RP, Wong VWS, Wong GLH, Shu SST, Chan HLY, Fung J, et al. Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong. Hepatol Res. 2020;50(9):1024–1031. doi: 10.1111/hepr.13535. [DOI] [PubMed] [Google Scholar]
- 5.Cotter TG, Dong L, Holmen J, Gilroy R, Krong J, Charlton M. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. J Gastroenterol. 2020;55(7):722–730. doi: 10.1007/s00535-020-01684-w. [DOI] [PubMed] [Google Scholar]
- 6.Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559–1569. doi: 10.1056/NEJMoa2029349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, et al. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia. J Gastroenterol Hepatol. 2022;37(12):2313–2320. doi: 10.1111/jgh.16019. [DOI] [PubMed] [Google Scholar]
- 8.Tamaki N, Kurosaki M, Huang DQ, Loomba R. Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. Hepatol Res. 2022;52(6):497–507. doi: 10.1111/hepr.13764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, et al. Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest. 2022;132(21):e162513. doi: 10.1172/JCI162513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tamaki N, Imajo K, Sharpton S, Jung J, Kawamura N, Yoneda M, et al. Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. Hepatology. 2022;75(3):661–672. doi: 10.1002/hep.32145. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–344. doi: 10.1038/nrgastro.2013.41. [DOI] [PubMed] [Google Scholar]
- 12.Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi: 10.1038/nrendo.2017.151. [DOI] [PubMed] [Google Scholar]
- 13.Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi: 10.1016/S2468-1253(19)30039-1. [DOI] [PubMed] [Google Scholar]
- 14.Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128. doi: 10.1111/hepr.13685. [DOI] [PubMed] [Google Scholar]
- 15.Tamaki N, Kurosaki M, Higuchi M, Izumi N. Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease. Hepatol Res. 2021;51(11):1172–1173. doi: 10.1111/hepr.13700. [DOI] [PubMed] [Google Scholar]
- 16.Zhang P, Dong X, Zhang W, Wang S, Chen C, Tang J, et al. Metabolic-associated fatty liver disease and the risk of cardiovascular disease. Clin Res Hepatol Gastroenterol. 2022;47(1):102063. doi: 10.1016/j.clinre.2022.102063. [DOI] [PubMed] [Google Scholar]
- 17.Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–121. doi: 10.1053/j.gastro.2005.04.014. [DOI] [PubMed] [Google Scholar]
- 18.Kogiso T, Tokushige K. The current view of nonalcoholic fatty liver disease-related hepatocellular carcinoma. Cancers (Basel) 2021;13(3):516. doi: 10.3390/cancers13030516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. J Gastroenterol Hepatol. 2020;35(9):1579–1589. doi: 10.1111/jgh.14989. [DOI] [PubMed] [Google Scholar]
- 20.Tamaki N, Higuchi M, Kurosaki M, Loomba R, Izumi N, MRCH Liver Study Group Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(5):1171–1173.e2. doi: 10.1016/j.cgh.2021.07.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Kamada Y, Takahashi H, Shimizu M, Kawaguchi T, Sumida Y, Fujii H, et al. Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol. 2021;56(12):1045–1061. doi: 10.1007/s00535-021-01833-9. [DOI] [PubMed] [Google Scholar]
- 22.Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2021;S1542–3565(21):01276–1283. doi: 10.1016/j.cgh.2021.11.038. [DOI] [PubMed] [Google Scholar]
- 23.Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951–963. doi: 10.1007/s00535-021-01796-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54(3):1082–1090. doi: 10.1002/hep.24452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Inada K, Kirino S, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol. 2021;36(10):2960–2966. doi: 10.1111/jgh.15589. [DOI] [PubMed] [Google Scholar]
- 26.Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1(5):212–28. doi: 10.1111/j.2040-1124.2010.00074.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018;25(9):846–984. doi: 10.5551/jat.GL2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) Hypertens Res. 2019;42(9):1235–1481. doi: 10.1038/s41440-019-0284-9. [DOI] [PubMed] [Google Scholar]
- 29.Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi: 10.1038/bmt.2012.244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Arvind A, Henson JB, Osganian SA, Nath C, Steinhagen LM, Memel ZN, et al. Risk of cardiovascular disease in individuals with Nonobese nonalcoholic fatty liver disease. Hepatol Commun. 2022;6(2):309–319. doi: 10.1002/hep4.1818. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Weinberg EM, Trinh HN, Firpi RJ, Bhamidimarri KR, Klein S, Durlam J, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases. Clin Gastroenterol Hepatol. 2021;19(5):996–1008.e6. doi: 10.1016/j.cgh.2020.06.066. [DOI] [PubMed] [Google Scholar]
- 32.Lan Y, Lu Y, Li J, Hu S, Chen S, Wang Y, et al. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China. Hepatol Commun. 2022;6(12):3393–3405. doi: 10.1002/hep4.2081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol. 2017;15(10):1604–1611.e1. doi: 10.1016/j.cgh.2017.04.045. [DOI] [PubMed] [Google Scholar]
- 34.Lin H, Wong GLH, Whatling C, Chan AWH, Leung HHW, Tse CH, et al. Association of genetic variations with NAFLD in lean individuals. Liver Int. 2022;42(1):149–160. doi: 10.1111/liv.15078. [DOI] [PubMed] [Google Scholar]
- 35.Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology. 2021;74(4):2241–2250. doi: 10.1002/hep.32047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 2012;91(6):319–327. doi: 10.1097/MD.0b013e3182779d49. [DOI] [PubMed] [Google Scholar]
- 37.Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–873. doi: 10.1016/j.jhep.2017.06.003. [DOI] [PubMed] [Google Scholar]
- 38.Wei JL, Leung JCF, Loong TCW, Wong GLH, Yeung DKW, Chan RSM, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol. 2015;110(9):1306–14. doi: 10.1038/ajg.2015.235. [DOI] [PubMed] [Google Scholar]
- 39.Wijarnpreecha K, Li F, Lundin SK, Suresh D, Song MW, Tao C, et al. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities. Aliment Pharmacol Ther. 2023;57(9):1014–1027. doi: 10.1111/apt.17424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M, et al. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. Hepatol Int. 2021;15(2):366–379. doi: 10.1007/s12072-021-10143-4. [DOI] [PubMed] [Google Scholar]
- 41.Fujii H, Iwaki M, Hayashi H, Toyoda H, Oeda S, Hyogo H, et al. Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients: a multicenter registry-based cohort study. Clin Gastroenterol Hepatol. 2022;S1542–3565(22):00008–8. doi: 10.1016/j.cgh.2022.01.002. [DOI] [PubMed] [Google Scholar]
- 42.Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18(1):55–66. doi: 10.1038/s41574-021-00584-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, et al. Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. Aliment Pharmacol Ther. 2022;55(3):292–301. doi: 10.1111/apt.16745. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets generated and analyzed during the current study are not publicly available due (because the datasets have personal information) but are available from the corresponding author on reasonable request.